Table 2.

Association between the mean percentage change in EPO dose during the sub-11 period and the risk of death over the subsequent 6 mo

VariableAdjusted HR (95% CI)a (n = 5974)
Mean dose increase (%) (months 4 to 6)
    < 01.09 (0.85 to 1.39)
    0 to 12.51.0 (–)
    >12.5 to 250.94 (0.76 to 1.16)
    >25 to 37.50.89 (0.69 to 1.13)
    > 37.50.86 (0.69 to 1.08)
Mean hemoglobin (g/dl) (month 6)
    < 91.90 (1.50 to 2.40)
    9 to <9.51.59 (1.24 to 2.04)
    9.5 to <101.39 (1.11 to 1.75)
    10 to <10.51.23 (0.99 to 1.53)
    10.5 to <11.01.0 (–)
Age (yr)
    < 451.0 (–)
    45 to <551.51 (1.09 to 2.09)
    55 to <651.68 (1.23 to 2.30)
    65 to <752.56 (1.88 to 2.48)
    75 to <852.81 (2.03 to 3.89)
    ≥ 853.90 (2.43 to 6.24)
Gender
    female0.83 (0.71 to 0.97)
    male1.0 (–)
Race
    white1.0 (–)
    black0.76 (0.64 to 0.89)
    other0.67 (0.49 to 0.92)
Body mass index (kg/m2)
    < 21.41.0 (–)
    21.4 to <24.21.08 (0.86 to 1.34)
    24.2 to <27.30.77 (0.61 to 0.98)
    27.3 to <32.20.86 (0.68 to 1.09)
    ≥ 32.20.71 (0.55 to 0.92)
Vascular access type at end of month 6
    catheter1.54 (1.24 to 1.91)
    fistula1.0 (–)
    graft1.24 (1.01 to 1.53)
Diabetes as primary cause of ESRD
    no1.0 (–)
    yes1.12 (0.95 to 1.32)
Number of hospitalizations (months 1 to 6)
    01.0 (–)
    1 to 21.49 (1.23 to 1.79)
    ≥ 32.02 (1.64 to 2.51)
Albumin (g/dl)
    < 3.51.0 (–)
    ≥ 3.50.45 (0.38 to 0.53)
Ferritin (ng/ml)
    < 1001.0 (–)
    100 to 5000.85 (0.64 to 1.13)
    > 5001.07 (0.91 to 1.26)
TSAT (%)
    < 20%1.0 (–)
    ≥ 20%0.85 (0.72 to 0.99)
  • a Adjusted for all other variables in the table and additional covariates not shown (systolic blood pressure, diastolic blood pressure, URR, and number of unplanned missed dialysis visits).

    HR, hazard ratio; CI, confidence interval.